Nan-Haw Chow, Ph.D.
E-mail:chownh@mail.ncku.edu.tw
TEL:06-2353535 ext 5288(off.) FAX:06-2766195
Educations / Professional Experience |
||
Educations |
1996 |
Institute of Pathology, College of Medicine, National Taiwan Universi Taipei, M.S |
China Medical College, Taichung, M.D. |
||
Current Position |
2012/8- |
Professor and Chairperson, Department of Pathology, College of Medicine, National Cheng Kung University |
2001- |
Professor, Department of Pathology, Medical College,National Cheng Kung University |
|
Professional Experience |
1996-2001 |
Associate professor, Department of Pathology, Medical College, National Cheng Kung University |
1989-1996 |
Assistant professor, Department of Pathology, Medical College, National Cheng Kung University |
|
1983-1986 |
Teaching assistant, Department of Pathology, Medical College, National Taiwan University |
|
1997-1998 |
Researcher,The Brady Urological Institute, The Johns Hopkins University |
Expertise /Research Interests |
|
Pathology, Tumor biology, Laboratory diagnosis |
|
Research Interests |
I. Genetic Model for Tumorigenesis of Human Bladder: The incidence of bladder cancer in southwest coast of Taiwan, where blackfoot disease is endemic, is unusu high. Epidemiological studies have established a strong link between arsenic exposure and bladder cancer; but mechanisms underlying transformation of normal urothelium to cancer cells remains to be elucidated. Moreover current treatment of patients with urinary tract cancer is still in preliminary stage, since not many clinicopatholog indicators are effective in predicting clinical outcome. As a result, our laboratory has been trying to establish a progression model for bladder carcinogenesis (Figure 1). We have tested a number of oncogenes and tumor suppressor genes for their relevance in human bladder cancer (1-6, 8, 9). Currently, two inducible c-met and RO expression systems have been extensively studied in our laboratory, and increasingly molecular genetic techniq (1-3, 8) and functional genomic approaches have been integrated into our investigation. We hope that novel molecular mechanisms or biotargets of bladder cancer could be discovered in the future.
II. Cancer Prevention and Anti-angiogenesis in Human Diseases:
Early diagnosis of urinary tract cancer remains the gold standard in improving clinical outome. It is well know field cancerization is an important characteristic of transitional cell carcinoma and may affect the natural course disease progression. As a result, it is imperative to modulate carcinogenesis as early as from the initiated cells i field mucosa. This is the basic rationale for chemoprevention. Animal studies found that soybean feeding has a protective effect on bladder carcinogenesis in Swiss albino mice and on a transplantable murine tumor. We and other investigators have reported that genistein (5,7,49-trihydroxyisoflavone), daidzein (7,49-dihydroxyisoflavon biochanin-A, and phytochemical concentrate tend to cause a dose-dependent inhibition of proliferation and indu of apoptosis on human cancer cells in vitro and in vivo (11). The molecular basis of anticancer effects of isoflav is under intensive investigation (5, 10). We will also extend this line of research to other constituents of foods or other natural compounds, as well as in other cancer types and Graves’s disease. |
Research Directions |
Functional genomics of urothelial carcinoma, Anti-angiogenesis in Human Diseases |